Intensification of maintenance therapy with infliximab in ulcerative colitis

Intensification of maintenance therapy with infliximab in ulcerative colitis

Bibliographic Details
Main Author:	Francesc Casellas
Format:	Article
Language:	English
Published:	Aran Ediciones
Series:	Revista Espanola de Enfermedades Digestivas
Online Access:	http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082015000900001&lng=en&tlng=en

Similar Items

Infliximab for ulcerative colitis.
by: Simmons, J, et al.
Published: (2002)

Infliximab for the treatment of acute exacerbations of ulcerative colitis
by: S Bryan, et al.
Published: (2010-05-01)

Therapeutic Drug Monitoring of Infliximab in Acute Severe Ulcerative Colitis
by: Benjamin L. Gordon, et al.
Published: (2023-05-01)

Vedolizumab is superior to infliximab in biologic naïve patients with ulcerative colitis
by: Renato Sablich, et al.
Published: (2023-02-01)

Autoimmune hemolytic anemia associated with infliximab infusion in ulcerative colitis
by: Fazia A. Mir, et al.
Published: (2018-02-01)

Infliximab for the treatment of ulcerative colitis: outcomes in Oxford from 2000 to 2006.
by: Jakobovits, S, et al.
Published: (2007)

Steroid-Refractory Acute Severe Ulcerative Colitis in Infliximab-Experienced Patients
by: Joana Revés, et al.
Published: (2024-03-01)

Case Report: Unusual Cause of Fever in Ulcerative Colitis Treated with Infliximab
by: Sha S, et al.
Published: (2023-03-01)

Protracted fever after infliximab induction therapy in a patient with ulcerative colitis (clinical case)
by: E. Yu. Chashkova, et al.
Published: (2022-12-01)

Review article: maintenance therapy in patients with ulcerative colitis.
by: Orchard, T, et al.
Published: (2006)

Evaluation of Proactive Therapeutic Drug Monitoring Application in Infliximab Users in Ulcerative Colitis
by: Gabriela Maria Henz Giovelli, et al.
Published: (2023-12-01)

Prediction and Verification of Potential Therapeutic Targets for Non-Responders to Infliximab in Ulcerative Colitis
by: Lyu X, et al.
Published: (2023-05-01)

Short-Term Response to Infliximab in Rheumatoid Pattern Polyarthropathy Complicating Ulcerative Colitis
by: ilke Coskun Benlidayi, et al.
Published: (2015-12-01)

Acute severe ulcerative colitis flare complicated by myopericarditis and infliximab-induced hepatitis
by: Magdalini Manti, et al.
Published: (2024-03-01)

Proteomic Analysis of Potential Targets for Non-Response to Infliximab in Patients With Ulcerative Colitis
by: Lu Liu, et al.
Published: (2022-06-01)

Editorial: what can be done when infliximab stops working in ulcerative colitis?
by: Boyapati, R, et al.
Published: (2015)

Ulcerative Colitis and Acute Severe Ulcerative Colitis Patients Are Overlooked in Infliximab Population Pharmacokinetic Models: Results from a Comprehensive Review
by: Alix Démaris, et al.
Published: (2022-09-01)

Rectal tuberculosis after infliximab therapy despite negative screening for latent tuberculosis in a patient with ulcerative colitis
by: Jatinderpal Singh, et al.
Published: (2016-04-01)

Racial Disparities in Infliximab Efficacy for Ulcerative Colitis: Evidence Synthesis and Effect Modification Assessment
by: Stefanos Bonovas, et al.
Published: (2024-01-01)

A case of nocardiosis in a patient with ulcerative colitis on chronic corticosteroids, infliximab, and upadacitinib
by: Benjamin M. Moy, et al.
Published: (2023-05-01)

Identified potential biomarkers may predict primary nonresponse to infliximab in patients with ulcerative colitis
by: Jixiang Zhang, et al.
Published: (2022-11-01)

Infliximab and Plant-Based Diet as First-Line Therapy Followed by Corticosteroid Therapy for Severe Ulcerative Colitis: A Case Report
by: Mitsuro Chiba, et al.
Published: (2022-09-01)

Colon salvage therapy for acute severe colitis: cyclosporine or infliximab?
by: Burger, D, et al.
Published: (2011)

Long-Term Risk of Colectomy in Patients with Severe Ulcerative Colitis Responding to Intravenous Corticosteroids or Infliximab
by: Elena De Cristofaro, et al.
Published: (2022-03-01)

Fulminant organizing pneumonia in a patient with ulcerative colitis on mesalamine and infliximab: striving to identify the cause!
by: Lídia Gomes, et al.
Published: (2023-07-01)

Colonic Dilatation Complicating Acute Severe Ulcerative Colitis Managed Successfully with Accelerated Infliximab Dosing
by: Hoang Huu Bui, et al.
Published: (2023-02-01)

The Impact of Intermediate Antidrug Antibodies to Infliximab and Adalimumab on Clinical Outcomes in Patients with Crohn’s Disease or Ulcerative Colitis
by: Chaoyang Wang, et al.
Published: (2022-03-01)

A comparison of short-term therapeutic efficacy between infliximab and tacrolimus for moderate to severe ulcerative colitis
by: Yamagami Hirokazu, et al.
Published: (2017-09-01)

Vedolizumab Attenuates Immune-Checkpoint-Therapy-Induced Infliximab-Refractory Colitis
by: Ayaka Kaneoka, et al.
Published: (2022-02-01)

Model-Informed Precision Dosing during Infliximab Induction Therapy Reduces Variability in Exposure and Endoscopic Improvement between Patients with Ulcerative Colitis
by: Ruben Faelens, et al.
Published: (2021-10-01)

C-reactive protein-to-albumin ratio and neutrophil-to-albumin ratio for predicting response and prognosis to infliximab in ulcerative colitis
by: Yanyan Zhang, et al.
Published: (2024-03-01)

Peritoneal Tuberculosis during Infliximab Treatment in a Patient with Ulcerative Colitis Despite a Negative Quantiferon Test
by: Anna Colombo, et al.
Published: (2021-04-01)

Infliximab use in ulcerative colitis flare with clostridium difficile infection: A report of two cases and literature review
by: Bhupinder S. Romana, et al.
Published: (2018-09-01)

Infliximab Induction Strategies in Corticosteroid-Refractory Acute Severe Ulcerative Colitis: A Case Series and Literature Review
by: Pedro Bernardes Antunes, et al.
Published: (2022-10-01)

Drug therapy of ulcerative colitis.
by: Crotty, B, et al.
Published: (1992)

Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis
by: Jairath, V, et al.
Published: (2017)

Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn’s disease and ulcerative colitis included in randomised controlled trials
by: Laurent Peyrin‐Biroulet, et al.
Published: (2024-03-01)

Efficacy of Switching to Adalimumab for Maintenance of Remission Following Induction Therapy with Tacrolimus in Patients with Ulcerative Colitis
by: Keijiro Numa, et al.
Published: (2023-10-01)

Therapy of ulcerative colitis: state of the art.
by: Brain, O, et al.
Published: (2008)

MESALAZINE PLACE IN THERAPY OF ULCERATIVE COLITIS
by: I. G. Bakulin, et al.
Published: (2017-11-01)